依洛尤单抗在高危糖尿病患者中的VESALIUS-CV试验结果
VESALIUS-CV预设分析纳入6002例无既往心梗或卒中但伴高危糖尿病(微血管病、胰岛素使用或病程≥10年)且LDL-C≥90 mg/dL的患者,随机接受依洛尤单抗140 mg或安慰剂每2周一次。中位随访4.6年,依洛尤单抗使3P-MACE相对风险降低29%(HR 0.71),4P-MACE降低21%(HR 0.79),全因死亡比例8.8% vs 11.0%(HR 0.79)。
要点
- 依洛尤单抗降低高危糖尿病患者3P-MACE风险29%(HR 0.71)。
- 获益不受是否合并动脉粥样硬化、基线LDL-C或背景用药影响。
- 全因死亡比例依洛尤单抗组8.8% vs 安慰剂组11.0%(HR 0.79)。
核心结论
- 依洛尤单抗降低高危糖尿病患者心血管事件发生率,且不依赖是否合并动脉粥样硬化及背景心血管保护药物使用。
研究设计与样本
- VESALIUS-CV预设分析,纳入6002例高危糖尿病且无既往心梗或卒中的患者,随机接受依洛尤单抗140 mg或安慰剂每2周一次。
主要发现
- 48周中位LDL-C在依洛尤单抗组为47 mg/dL,安慰剂组为109 mg/dL(P < 0.0001)。
- 中位随访4.6年,依洛尤单抗使3P-MACE相对风险降低29%(HR 0.71;95% CI 0.59, 0.86;P = 0.0004)。
- 依洛尤单抗使4P-MACE相对风险降低21%(HR 0.79;95% CI 0.69, 0.91;P = 0.0013)。
- 全因死亡比例依洛尤单抗组8.8% vs 安慰剂组11.0%(HR 0.79;95% CI 0.67, 0.93)。
- 各亚组(合并动脉粥样硬化、基线LDL-C、他汀强度、SGLT2i或GLP-1RA使用)交互P > 0.05。
关键数值与推荐
- 高危糖尿病定义:微血管病、胰岛素使用或糖尿病病程≥10年。
- 入组要求LDL-C ≥90 mg/dL且无既往心梗或卒中。
- 基线时67%使用高强度他汀,24%使用SGLT2i或GLP-1RA。
临床怎么用
- 对无既往心梗或卒中的高危糖尿病患者,可考虑依洛尤单抗以降低首发心血管事件风险。
- 依洛尤单抗的获益与是否合并动脉粥样硬化及背景SGLT2i或GLP-1RA使用无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This prespecified analysis of Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV) evaluated the efficacy of the PCSK9 inhibitor evolocumab for preventing first cardiovascular events in patients with high-risk diabetes. RESEARCH DESIGN AND METHODS: VESALIUS-CV randomized patients with high-risk diabetes (microvascular disease, insulin use, or duration ≥10 years) or qualifying atherosclerosis, but no prior myocardial infarction (MI) or stroke, and LDL cholesterol (LDL-C) ≥90 mg/dL to evolocumab 140 mg or matching placebo every 2 weeks. The dual primary end points were a composite of coronary heart disease death, MI or ischemic stroke (three-point major adverse cardiovascular event [3P-MACE]) and 3P-MACE plus ischemia-driven arterial revascularization (four-point [4P]-MACE). RESULTS: Of the 6,002 patients with high-risk diabetes, 67% were on a high-intensity statin and 24% were on a sodium-glucose cotransporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 receptor agonist (GLP-1RA) at baseline. The median LDL-C at 48 weeks was 47 mg/dL and 109 mg/dL in the evolocumab and placebo arms, respectively (P < 0.0001). After a median follow-up of 4.6 years, evolocumab decreased the relative rates of 3P-MACE and 4P-MACE by 29% (hazard ratio [HR] 0.71; 95% CI 0.59, 0.86; P = 0.0004) and 21% (HR 0.79; 95% CI 0.69, 0.91; P = 0.0013), respectively. These findings were consistent regardless of the presence or absence of qualifying atherosclerosis, baseline LDL-C, statin intensity, and SGLT2i or GLP-1RA use (Pint > 0.05 for each). The porportion of patients with all-cause death was 8.8% vs. 11.0% in the evolocumab versus placebo arms (HR 0.79; 95% CI 0.67, 0.93). CONCLUSIONS: Evolocumab reduced the rate of cardiovascular events in patients with high-risk diabetes, regardless of the presence or absence of qualifying atherosclerosis and background use of other cardioprotective agents.
引用
- Leiter LA, Giugliano RP, Marston NA, et al. Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial. Diabetes Care. 2026. PMID: 42251764. doi:10.2337/dc26-0847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。